Silva Pharmaceuticals Limited (DSE:SILVAPHL)
Bangladesh · Delayed Price · Currency is BDT 13.50
+0.30 (2.27%)
At close: Jun 16, 2026
Silva Pharmaceuticals Income Statement
Financials in millions BDT. Fiscal year is July - June.
Millions BDT. Fiscal year is Jul - Jun.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Jun '25 Jun 30, 2025 | Jun '24 Jun 30, 2024 | Jun '23 Jun 30, 2023 | Jun '22 Jun 30, 2022 | Jun '21 Jun 30, 2021 |
| 329.63 | 383.65 | 599.66 | 716.87 | 778.67 | 799.25 | |
Revenue Growth (YoY) | -23.64% | -36.02% | -16.35% | -7.94% | -2.57% | 4.71% |
Cost of Revenue | 244.19 | 283.13 | 437.91 | 487.58 | 492.89 | 486.26 |
Gross Profit | 85.44 | 100.51 | 161.75 | 229.29 | 285.78 | 312.99 |
Selling, General & Admin | 227.29 | 221.52 | 209.99 | 185.61 | 175.07 | 171.85 |
Other Operating Expenses | - | - | - | -1.1 | -1.05 | -0.94 |
Operating Expenses | 227.29 | 221.52 | 209.99 | 184.51 | 174.02 | 170.91 |
Operating Income | -141.85 | -121.01 | -48.25 | 44.78 | 111.76 | 142.09 |
Interest Expense | -3.67 | -4.48 | -4.38 | -3.61 | -4.71 | -2.78 |
Interest & Investment Income | 3.58 | 5.34 | 5.17 | 9.45 | 9.67 | 12.05 |
Other Non Operating Income (Expenses) | 0.17 | 0.58 | 0.96 | -0.26 | -0.05 | -0.02 |
Pretax Income | -141.76 | -119.58 | -46.5 | 50.36 | 116.67 | 151.35 |
Income Tax Expense | 12.42 | 13.37 | 17.99 | 17.29 | 14.41 | 31.49 |
Net Income | -154.19 | -132.95 | -64.48 | 33.08 | 102.26 | 119.85 |
Net Income to Common | -154.19 | -132.95 | -64.48 | 33.08 | 102.26 | 119.85 |
Net Income Growth | - | - | - | -67.65% | -14.68% | 0.77% |
Shares Outstanding (Basic) | 137 | 137 | 137 | 137 | 137 | 137 |
Shares Outstanding (Diluted) | 137 | 137 | 137 | 137 | 137 | 137 |
EPS (Basic) | -1.13 | -0.97 | -0.47 | 0.24 | 0.75 | 0.88 |
EPS (Diluted) | -1.13 | -0.97 | -0.47 | 0.24 | 0.75 | 0.88 |
EPS Growth | - | - | - | -67.65% | -14.68% | 0.92% |
Free Cash Flow | -13.93 | 6.49 | -29.57 | -16.7 | -16.8 | 82.22 |
Free Cash Flow Per Share | -0.10 | 0.05 | -0.22 | -0.12 | -0.12 | 0.60 |
Dividend Per Share | - | - | 0.100 | 0.100 | 0.300 | 0.500 |
Dividend Growth | - | - | - | -66.67% | -40.00% | - |
Gross Margin | 25.92% | 26.20% | 26.97% | 31.99% | 36.70% | 39.16% |
Operating Margin | -43.03% | -31.54% | -8.05% | 6.25% | 14.35% | 17.78% |
Profit Margin | -46.78% | -34.65% | -10.75% | 4.61% | 13.13% | 15.00% |
Free Cash Flow Margin | -4.23% | 1.69% | -4.93% | -2.33% | -2.16% | 10.29% |
EBITDA | -88.24 | -63.18 | 10.54 | 107.29 | 174.33 | 207.38 |
EBITDA Margin | -26.77% | -16.47% | 1.76% | 14.97% | 22.39% | 25.95% |
D&A For EBITDA | 53.6 | 57.83 | 58.79 | 62.51 | 62.57 | 65.29 |
EBIT | -141.85 | -121.01 | -48.25 | 44.78 | 111.76 | 142.09 |
EBIT Margin | -43.03% | -31.54% | -8.05% | 6.25% | 14.35% | 17.78% |
Effective Tax Rate | - | - | - | 34.33% | 12.35% | 20.81% |
Advertising Expenses | - | 5.37 | 3.82 | 3.81 | 5.92 | 20.65 |